Slingshot members are tracking this event:
FDA Approves Celgene's (CELG) REVLIMID in Treating Multiple Myeloma (MM) Following Autologous Stem Cell Transplant (ASCT)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 22, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Revlimid, Multiple Myeloma, Autologous Stem Cell Transplant